Development of the Schwartz-Bartter syndrome after the administration of chlorpropamide and 1-deamino-8-D-arginine vasopressin.
D001127:Arginine Vasopressin / Q000031:analogs & derivatives*; D001834:Body Water / Q000378:metabolism; D002747:Chlorpropamide / Q000009:adverse effects*; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000031:analogs & derivatives*; D048909:Diabetes Complications; D003919:Diabetes Insipidus / Q000209:etiology*; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000150:complications*; D008297:Male; D008875:Middle Aged; D011141:Polyuria / Q000209:etiology; D013997:Time Factors; D014667:Vasopressins / Q000097:blood
D014667:Vasopressins; D001127:Arginine Vasopressin; C025161:vasopressin, deamino-homo-Arg-; D003894:Deamino Arginine Vasopressin; D002747:Chlorpropamide